U51 / Shanghai Unicar - LARVOL DELTA

5-Year Follow-up of Combined Infusion of Anti-CD19 and Anti-BCMA CAR-T after ASCT for High-Risk Newly Diagnosed Multiple Myeloma (ASH 2024) - P1/2 | "Our preliminary study showed that anti-CD19 and anti-BCMA CAR-T cell therapy followed by lenalidomide maintenance after ASCT yielded encouraging activity for high-risk NDMM...Conclusions : To the best of our knowledge, this is the first clinical trial to incorporate anti-BCMA and anti-CD19 CAR-T cells as consolidation therapy for high-risk NDMM patients...This novel therapeutic strategy shows promise in addressing the unmet needs of high-risk NDMM patients, potentially offering a new direction in the management of this challenging subgroup of multiple myeloma. Further studies are warranted to confirm these encouraging results and to fully elucidate the role of dual-target CAR-T cell therapy in the treatment paradigm for high-risk NDMM."

Hematological Malignancies • Multiple Myeloma • Oncology • IL6

Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial (ASH 2024) - "According to previous literature, the incidence of peripheral neuropathy (PN) related to bortezomib was approximately 40%, and even up to 70% in patients treated with thalidomide, which adversely impacted quality of life (QoL) for the patients. The BiRD regimen (clarithromycin, lenalidomide and dexamethasone) was evaluated for NDMM (newly diagnosed MM) patients in 2008, which demonstrated good efficacy and tolerance without neurotoxicity...Moreover, an improvement of most QoL domains of the QLQ-C30 and QLQ-MY20 was observed from baseline to the period after BCMA CAR T cell, especially pain and disease symptom. Conclusion This study firstly demonstrates that BiRD regimen followed by anti-BCMA CAR T-cell therapy can induce deep and early remission for NDMM patients with good tolerance even for high risk patients, providing a novel front-line treatment option for NDMM."

CAR T-Cell Therapy • Clinical • P3 data • Anemia • Cardiovascular • Fatigue • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Oncology • Pain • Peripheral Neuropathic Pain • Respiratory Diseases • Thrombocytopenia

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma. (PubMed, J Transl Med) - "Our results confirmed that BCMA CAR T-cell therapy combined with long-term pomalidomide had a low recurrence rate and manageable therapy-related side effects, providing a promising option for treating R/R MM."

Journal • Retrospective data • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology

PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion. (PubMed, J Immunother Cancer) - "Our study demonstrates a design concept of CAR-T cells independent of antigen specificity and provides an alternative approach for improving the efficacy of CAR-T cell therapy."

CAR T-Cell Therapy • IO biomarker • Journal • Hematological Malignancies • Multiple Myeloma • Oncology • PD-1

Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. (PubMed, Am J Hematol) - P1/2 | "Although the sample size was small and there was a lack of control in this single-arm study, the clinical benefits observed warrant ongoing randomized controlled trials. This trial was registered at ClinicalTrials.gov (NCT03455972)."

CAR T-Cell Therapy • Journal • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Oncology • Transplantation

Anti-BCMA CAR T-Cell Therapy for R/R ITP (clinicaltrials.gov) - P2 | N=5 | Recruiting | Sponsor: The First Affiliated Hospital of Soochow University

CAR T-Cell Therapy • New P2 trial • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura

Immunoglobulin Isotype Switch after Anti-BCMA CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma. (PubMed, Blood Adv) - No abstract available

CAR T-Cell Therapy • Journal • Hematological Malignancies • Multiple Myeloma • Oncology

Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients (clinicaltrials.gov) - P3; N=20; Recruiting; Sponsor: The First Affiliated Hospital of Soochow University; N=30 ➔ 20

CAR T-Cell Therapy • Clinical • Enrollment change • Hematological Malignancies • Multiple Myeloma • Oncology

Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients (clinicaltrials.gov) - P3; N=30; Recruiting; Sponsor: The First Affiliated Hospital of Soochow University; Trial completion date: Jan 2024 ➔ Jan 2025; Trial primary completion date: Jan 2022 ➔ Jan 2023

CAR T-Cell Therapy • Clinical • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology